| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 4384 | 2018 |
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500-504, 2012 | 2026 | 2012 |
| The human tumor microbiome is composed of tumor type–specific intracellular bacteria D Nejman, I Livyatan, G Fuks, N Gavert, Y Zwang, LT Geller, ... Science 368 (6494), 973-980, 2020 | 1795 | 2020 |
| Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG De Boer, ... Cell 175 (4), 998-1013. e20, 2018 | 1661 | 2018 |
| Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ... Science 357 (6356), 1156-1160, 2017 | 1579 | 2017 |
| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1493 | 2016 |
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma DT Frederick, A Piris, AP Cogdill, ZA Cooper, C Lezcano, CR Ferrone, ... Clinical cancer research 19 (5), 1225-1231, 2013 | 1023 | 2013 |
| Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer, PA Prieto, JP Miller, ... Cancer discovery 6 (8), 827-837, 2016 | 1003 | 2016 |
| Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance W Roh, PL Chen, A Reuben, CN Spencer, PA Prieto, JP Miller, ... Science translational medicine 9 (379), eaah3560, 2017 | 822 | 2017 |
| The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ... Nature genetics 47 (3), 250-256, 2015 | 581 | 2015 |
| A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors DJ Konieczkowski, CM Johannessen, O Abudayyeh, JW Kim, ZA Cooper, ... Cancer discovery 4 (7), 816-827, 2014 | 559 | 2014 |
| MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition N Wagle, EM Van Allen, DJ Treacy, DT Frederick, ZA Cooper, ... Cancer discovery 4 (1), 61-68, 2014 | 549 | 2014 |
| BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice C Liu, W Peng, C Xu, Y Lou, M Zhang, JA Wargo, JQ Chen, HS Li, ... Clinical cancer research 19 (2), 393-403, 2013 | 423 | 2013 |
| sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance A Kaur, MR Webster, K Marchbank, R Behera, A Ndoye, CH Kugel, ... Nature 532 (7598), 250-254, 2016 | 399 | 2016 |
| Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ... Clinical Cancer Research 18 (19), 5329-5340, 2012 | 339 | 2012 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 318 | 2021 |
| Elucidating Distinct Roles for NF1 in Melanomagenesis O Maertens, B Johnson, P Hollstein, DT Frederick, ZA Cooper, ... Cancer discovery 3 (3), 338-349, 2013 | 315 | 2013 |
| Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised … RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ... The lancet oncology 19 (2), 181-193, 2018 | 305 | 2018 |
| Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6: 202–216. doi: 10.1158/2159-8290 W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... CD-15-0283, 2018 | 271 | 2018 |
| Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade ZA Cooper, VR Juneja, PT Sage, DT Frederick, A Piris, D Mitra, JA Lo, ... Cancer immunology research 2 (7), 643-654, 2014 | 269 | 2014 |
Dennie T. FrederickMassachusetts General HospitalPatvirtintas el. paštas mgh.harvard.edu